DESCRIPTION

This activity's goal is to join community-based providers and academic oncologists to improve the care and outcomes of patients with hematologic malignancies. To reach this goal, this activity will address early treatment options and medical advances that can be implemented to reduce cancer-related deaths, including CAR T-cell therapy and novel therapeutics for the state-of-the-art management of newly-diagnosed and relapsed blood cancers. It will keep all healthcare professionals who care for patients with hematologic malignancies abreast of the latest scientific updates, innovative ideas, and timeliest issues related to their care.

It will also provide participants with information to improve patient management and care strategies. They will discuss rapidly evolving developments, discover new treatments for patients, and improve practice paradigms. This activity will educate them on best practices for treating hematologic cancers and inform them of the indications to refer a patient for expert quaternary level care for advanced cellular therapies.

TARGET AUDIENCE

This activity is designed for primary care physicians, hematologists, pathologists, medical oncologists, trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to treating hematologic cancers.

LEARNING OBJECTIVES

After this activity, participants will be able to:

- Illustrate how cutting-edge data presented at the 2022 Annual Meeting of the American Society of Hematology can apply to clinical practice;
- State the emerging treatment strategies for patients with low-risk and high-risk myeloid malignancies;
- Discuss the optimal patient selection, timing, and regimen for transplant;
- Evaluate clinical trial data in the context of CAR T-cell therapy and its place in evolving hematologic malignancy treatment standards;
- Choose the optimal treatment, sequencing, and supportive care strategies for patients with lymphoma using evidence-based guidelines;
- Identify methods for integrating therapeutic advances into practice to improve current myeloma patient care;
- Describe the pathogenesis, diagnostic evaluation, and therapeutic modalities available for common benign hematologic diseases and COVID-associated hematologic diseases.

ACCREDITATION AND CREDIT DESIGNATION

Physician Credit

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 7.25 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit
University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Participants who successfully complete the entire activity and complete an evaluation form will earn 7.25 contact hours.

American Board of Internal Medicine MOC II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pediatrics MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.25 MOC points in the American Board of Pediatrics's (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

Other Healthcare Professional Credit
Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME, please consult your professional licensing board.

EDUCATIONAL GRANTS/COMMERCIAL SUPPORT

Educational grant funding has been generously provided by:

ADC Therapuetics	AstraZeneca	Jazz Pharmaceuticals

We also thank our exhibitors:

Platinum Level

BeiGene Pharmaceuticals	Blueprint Medicines	Genentech Hematology

Gold Level

ADC Therapeutics	Incyte	Seagen
Astellas Pharma	MorphoSys US Inc.	Servier
Astra Zeneca (Hematology)	Novartis	
Bristol Myers Squibb	Sanofi (Oncology)	

Silver Level

AbbVie	GSK (Oncology)	Takeda Pharmaceutical
Adaptive Biotechnologies	Jazz Pharmaceuticals	Company Oncology

Bronze Level

Agios Pharmaceuticals	Eli Lilly and Company	Pfizer (Oncology)
EUSA Pharma	Merck & Co.	PharmaEssentia, USA
Janssen Pharmaceuticals	Omeros	Rigel Pharmaceuticals, Inc.
Kite Pharma	Pfizer	Sanofi (Transplant)

Non-Profit Level

The Leukemia and Lymphoma Society	The National Marrow Donor Program

DISCLOSURE DECLARATIONS

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control the content of an education activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if a financial relationship, in any amount, exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, The University of Chicago Pritzker School of Medicine requires Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration at first mention and where appropriate in the content.

COURSE FACULTY

The following individuals have no relevant financial relationships with ineligible companies to disclose:

Luca Capicchioni, MSL
Jennifer Cooperrider, MD
Satyajit Kosuri, MD
Javier Macias
Rafael Madero-Marroquin, MD
Rebecca Malloy, RN
Mylove Mortel, MSPH, RN, OCN
Alexandra Rojek, MD
Linda Schroeder, RN

Michael R. Bishop, MD has served on the advisory board of Bristol Myers Squibb, Novartis, Kite/Gilead, ADC Therapeutics, AstraZeneca, Incyte, CRISPR Therapeutics, and Servier Bio and on the speakers' bureau of Bristol Myers Squibb, Kite/Gilead, ADC Therapeutics, AstraZeneca, Incyte, Sanofi, Agios, and Servier Bio.

Kenneth Cohen, MD has no relevant financial relationships with ineligible companies to disclose. Dr. Cohen will discuss the off-label use of efgartigimod.

Benjamin Derman, MD has served as a consultant for Sanofi and Janssen.

Adam DuVall, MD, MPH has served on the advisory board of Jazz Pharma.

Andrea Fadel, RN has no relevant financial relationships with ineligible companies to disclose. Andrea will present case studies of patients who were on clinical trials.

Justin Kline, MD has served as a speaker for Kite/Gilead and as a consultant for Gilead, Seagen, Morphosys, Daiichi Sankyo, and Secura Bio.

Andrzej Jakubowiak, MD, PhD served on the advisory board and as a consultant for AbbVie, Amgen, BMS, GSK, and Sanofi. Dr. Jakubowiak will discuss the investigational/unapproved use of a commercial product.

Hongtao Liu, MD, PhD has served on the advisory board of Agios, Pfizer, CTI Biopharm, and Servier.

Mariam Nawas, MD has no relevant financial relationships with ineligible companies to disclose. Dr. Nawas will discuss the investigational/unapproved use of a commercial product.

Toyosi Odenike, MD has served on the advisory board of BMS, Taiho, and CTI Biopharma. Dr. Odenike has received research funding from AbbVie, Agios, AstraZeneca, Bristol Myers Squibb, Celgene, CTI, Daiichi, Incyte, Janssen, Novartis, and NS-Pharma. Dr. Odenike will discuss the investigational use of epigenetic modulators and kinase inhibitors in myeloid neoplasms.

Anand Patel, MD has served as a consultant for AbbVie and has received research funding from Pfizer and BMS. Dr. Patel will be discussing agents utilized in clinical trials that are presented at the ASH 2022 annual meeting and may not be FDA approved.

Peter Riedell, MD has served as a consultant for Kite/Gilead, Novartis, BeiGene, BMS, CVS Caremark, and Nektar Therapeutics and as a speaker for Kite/Gilead. Dr. Riedell served as an advisory board member for Kite/Gilead, Novartis, AbbVie, BMS, Janssen, Karyopharm Therapeutics, Takeda, and ADC Therapeutics and received research funding from Kite/Gilead, Novartis, BMS, CRISPR Therapeutics, and MorphoSys.

Laurie Sehn, MD has received research funding from Roche/Genentech and has served as a consultant for Roche/Genentech, Seattle Genetics, Teva, Janssen, Incyte, Kite/Gilead, BMS/Celgene, AstraZeneca, and AbbVie. Dr. Sehn will discuss ongoing clinical trial updates that may include not-yet approved indications.

Sonali Smith, MD has served as a consultant for Morphosys, Gilead, and BMS and has received research funding from Epizyme, Pharmacyclics, FortySeven, Karyopharm, BMS, Acerta, Genentech, Portola, Curis, and Celgene.

The staff of the Center for Continuing Medical Education have no relevant financial relationships with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated.

DISCLAIMER

The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Please Note: Requests to claim *AMA PRA Category 1 Credit*™ after three months will be subject to additional fees.